Provectus Biopharmaceuticals Inc (OTC: PVCT) is a clinical-stage biopharmaceutical company developing prescription drug candidates based on its proprietary rose bengal sodium (RBS) molecule. The company has no product revenues as of December 31, 2025, and funds operations through equity sales and financing arrangements. Its lead drug candidate, PV-10, is an intratumoral formulation of pharmaceutical-grade RBS that previously advanced through a multi-country, multi-center Phase 3 randomized controlled trial for locally advanced cutaneous melanoma (LACM), with Chemistry, Manufacturing and Control (CMC) data accepted by seven national drug regulatory agencies including the U.S. FDA, Germany's BfArM, Australia's TGA, France's ANSM, Italy's AIFA, Mexico's COFEPRIS, and Argentina's ANMAT. The company holds a proprietary, patented commercial-scale synthesis process for RBS as an active pharmaceutical ingredient (API). As of December 31, 2025, Provectus carried an accumulated deficit of $262,853,811 and its auditors have raised substantial doubt about its ability to continue as a going concern.

Revenue model

Provectus generates no product revenue as of December 31, 2025. The company anticipates future revenues from product sales or out-licensing arrangements if drug candidates receive regulatory approval. Operations are funded through equity issuances and external financing. Unearned grant revenue appeared on prior balance sheets but showed a zero balance as of December 31, 2025.

Products and services

PV-10: an intratumoral drug candidate formulated from pharmaceutical-grade RBS (rose bengal sodium) API, previously studied in a Phase 3 trial for locally advanced cutaneous melanoma. Additional RBS formulations at various concentrations and routes of administration are in pre-clinical or early-stage development for other disease areas, with goals to file INDs or pursue co-development and out-licensing arrangements.

Customers and end markets

No commercial customers as of December 31, 2025. Target end markets are oncology and other disease areas where RBS-based drug candidates may demonstrate clinical activity. Intended end users are patients and physicians in markets where regulatory approval may eventually be granted.

Value-chain role

Provectus operates as a drug developer and IP holder. It owns a patented commercial-scale synthesis process for pharmaceutical-grade RBS API, develops CMC specifications, conducts or sponsors clinical trials, and seeks co-development or out-licensing partnerships for commercialization rather than manufacturing or distributing finished pharmaceutical products itself.

Geographic exposure

Clinical development activities have spanned the United States, Germany, Australia, France, Italy, Mexico, and Argentina, based on the seven national regulatory agencies that reviewed CMC data for the prior Phase 3 trial. The company is incorporated in the United States.

Source: SEC 10-K, filed 2026-03-26

Industry: Pharmaceutical Preparations Peers: Acer Therapeutics Inc. Biofrontera Inc Context Therapeutics Inc CalciMedica Inc Johnson & Johnson LANNETT CO INC Traws Pharma Inc